A xenotransplantation model for reactivation of paternal UBE3A using human-specific antisense oligonucleotides

1. Van Buggenhout, G. & Fryns, J. P. Angelman syndrome (AS, MIM 105830). Eur. J. Hum. Genet. 17, 1367–1373 (2009).

   Google Scholar 

2. LaSalle, J. M., Reiter, L. T. & Chamberlain, S. J. Epigenetic regulation of UBE3A and roles in human neurodevelopmental disorders. Epigenomics 7, 1213–1228 (2015).

   Google Scholar 

3. Silva-Santos, S. et al. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. J. Clin. Invest. 125, 2069–2076 (2015).

   Google Scholar 

4. Yang, Q., Zhao, J., Chen, D. & Wang, Y. E3 ubiquitin ligases: styles, structures and functions. Mol. Biomed. 2, 23 (2021).

   Google Scholar 

5. Chamberlain, S. J. & Lalande, M. Neurodevelopmental disorders involving genomic imprinting at human chromosome 15q11–q13. Neurobiol. Dis. 39, 13–20 (2010).

   Google Scholar 

6. Yamasaki, K. et al. Neurons but not glial cells show reciprocal imprinting of sense and antisense transcripts of Ube3a. Hum. Mol. Genet. 12, 837–847 (2003).

   Google Scholar 

7. Rougeulle, C., Cardoso, C., Fontés, M., Colleaux, L. & Lalande, M. An imprinted antisense RNA overlaps UBE3A and a second maternally expressed transcript. Nat. Genet. 19, 15–16 (1998).

   Google Scholar 

8. Rinaldi, C. & Wood, M. J. A. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9–21 (2018).

   Google Scholar 

9. Finkel, R. S. et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 377, 1723–1732 (2017).

   Google Scholar 

10. Aartsma-Rus, A. & Corey, D. R. The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy. Nucleic Acid Ther. 30, 67–70 (2020).

    Google Scholar 

11. Hipp, J. F. et al. The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial. Nat. Med. 2025, 1–10 (2025).

    Google Scholar 

12. Lee, H. M. et al. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome. Mol. Autism. 9, 45 (2018).

    Google Scholar 

13. Vihma, H. et al. Ube3a unsilencer for the potential treatment of Angelman syndrome. Nat. Commun. 15, 1–16 (2024).

14. Milazzo, C. et al. Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model. JCI Insight 6 (2021).

15. Meng, L. et al. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 518, 409–412 (2014).

    Google Scholar 

16. Dindot, S. V. et al. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript. Sci. Transl Med. 15, eabf4077 (2023).

    Google Scholar 

17. Germain, N. D. et al. Antisense oligonucleotides targeting UBE3A-ATS restore expression of UBE3A by relieving transcriptional interference. bioRxiv 2021.07.09.451826 (2021).

18. Jagasia, R. et al. Angelman syndrome patient-derived neuron screen leads to clinical ASO rugonersen targeting UBE3A-ATS with long-lasting effect in monkeys. Nucleic Acids Res. 53, gkaf851 (2025).

    Google Scholar 

19. Daneman, R. & Prat, A. The Blood–Brain Barrier. Cold Spring Harb Perspect. Biol. 7, a020412 (2015).

    Google Scholar 

20. Stanurova, J. et al. Angelman syndrome-derived neurons display late onset of paternal UBE3A silencing. Sci. Rep. 6, 30792 (2016).

    Google Scholar 

21. Gunhanlar, N. et al. A simplified protocol for differentiation of electrophysiologically mature neuronal networks from human induced pluripotent stem cells. Mol. Psychiatry. 23, 1336–1344 (2018).

    Google Scholar 

22. Frega, M. et al. Rapid neuronal differentiation of induced pluripotent stem cells for measuring network activity on micro-electrode arrays. J. Vis. Exp. 2017, 54900 (2017).

23. Elgersma, Y. A molecular tightrope. Nature 526, 50–51 (2015).

    Google Scholar 

24. Meng, L., Person, R. E. & Beaudet, A. L. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a. Hum. Mol. Genet. 21, 3001–3012 (2012).

    Google Scholar 

25. Avagliano Trezza, R. et al. Loss of nuclear UBE3A causes electrophysiological and behavioral deficits in mice and is associated with Angelman syndrome. Nat. Neurosci. 22, 1235–1247 (2019).

    Google Scholar 

26. Nuber, U., Schwarz, S. E. & Scheffner, M. The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. Eur. J. Biochem. 254, 643–649 (1998).

    Google Scholar 

27. Scoles, H. A., Urraca, N., Chadwick, S. W., Reiter, L. T. & Lasalle, J. M. Increased copy number for methylated maternal 15q duplications leads to changes in gene and protein expression in human cortical samples. Mol. Autism. 2, 19 (2011).

    Google Scholar 

28. Elamin, M. et al. The role of UBE3A in the autism and epilepsy-related Dup15q syndrome using patient-derived, CRISPR-corrected neurons. Stem Cell. Rep. 18, 884–898 (2023).

    Google Scholar 

29. Chen, X. et al. Antisense oligonucleotide therapeutic approach for Timothy syndrome. Nature 628, 818–825 (2024).

    Google Scholar 

30. Wang, T. et al. Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nat. Commun. 11, 4932 (2020).

    Google Scholar 

31. Cheerie, D. et al. Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments. Am. J. Hum. Genet. 112, 975–983 (2025).

    Google Scholar 

32. Friedman, J. M. et al. Genomic newborn screening: public health policy considerations and recommendations. BMC Med. Genomics. 10, 9 (2017).

    Google Scholar 

33. Yuan, S. H. et al. Cell-Surface Marker Signatures for the Isolation of Neural Stem Cells, Glia and Neurons Derived from Human Pluripotent Stem Cells. PLoS One. 6, e17540 (2011).

    Google Scholar 

34. Lendemeijer, B. et al. Human pluripotent stem cell-derived astrocyte functionality compares favorably with primary rat astrocytes. eNeuro 11, ENEURO.0148-24.2024 (2024).

35. Van Til, N. P. et al. Correction of murine rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. Mol. Ther. 20, 1968–1980 (2012).

    Google Scholar 

36. Toonen, L. J. A. et al. Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain. Nucleic Acid Ther. 28, 63–73 (2018).

    Google Scholar 

37. Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods. 9, 676–682 (2012).

    Google Scholar 

38. O’Geen, H. et al. Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model. Mol. Ther. 31, 1088–1105 (2023).

    Google Scholar 

Download references

Author notes

1. Hilde Smeenk and Bas Lendemeijer contributed equally to this work. Femke M.S. de Vrij and Steven A. Kushner jointly supervised this work.

Authors and Affiliations

1. Department of Psychiatry, Erasmus MC University Medical Center, Rotterdam, The Netherlands

   Hilde Smeenk, Bas Lendemeijer, Mirle G. Buurma, Michell A. Forgione, Denise E. Slump, Witte J. G. Hoogendijk & Femke M. S. de Vrij

2. Stavros Niarchos Foundation (SNF) Center for Precision Psychiatry & Mental Health, Columbia University, New York, NY, USA

   Bas Lendemeijer & Steven A. Kushner

3. Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands

   Roos A. Monshouwer, Ilse Wallaard, Edwin J. Mientjes & Ype Elgersma

4. Erasmus MC Expertise Center for Neurodevelopmental Disorders (ENCORE), Erasmus MC University Medical Center, Rotterdam, The Netherlands

   Edwin J. Mientjes, Ype Elgersma & Femke M. S. de Vrij

5. Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA

   Steven A. Kushner

Contributions

The author contributions were as follows: experimental design: H.S., B.L., I.W., E.J.M, Y.E., F.M.S.d.V., S.A.K; data acquisition: H.S., B.L., M.G.B., M.A.F., R.A.M., D.E.S.; data analysis: H.S., B.L; writing the manuscript: H.S., B.L., F.M.S.d.V., S.A.K.; review of manuscript: all authors; supervision: E.J.M., W.J.G.H., Y.E., F.M.S.d.V., S.A.K.; H.S. and B.L. contributed equally to the manuscript; F.M.S.d.V. and S.A.K. contributed equally to the manuscript.

Corresponding authors

Correspondence to Femke M. S. de Vrij or Steven A. Kushner.

Competing interests

The authors declare no competing interests.

Ethical approval

All methods were performed in accordance with the relevant guidelines and regulations. In addition, all mouse experiments were conducted in accordance with ARRIVE guidelines and the European Commission Council Directive 2010/63/EU. We obtained national and local approval under CCD license AVD1010020173544 and AVD10100202215931 (Centrale Commissie Dierproeven, the Hague, the Netherlands).

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions